Microsoft sued by Australia competition regulator over Copilot, 365 pricing
Decheng Capital, a major shareholder in BeyondSpring Inc. (NASDAQ: BYSI), has sold a portion of its holdings in the company. The micro-cap biotech firm, currently valued at $71 million, has seen its shares surge nearly 60% over the past six months. According to a Form 4 filing with the Securities and Exchange Commission, the sales occurred between October 8 and October 10, 2025. InvestingPro analysis indicates the company is quickly burning through cash, despite maintaining a good overall financial health score.
Decheng Capital China Life Sciences USD Fund III, L.P. sold 13,876 shares of BeyondSpring’s ordinary shares in three separate transactions for a total of $24,719. The prices for these shares ranged from $1.77 to $1.81. For deeper insights into insider transactions and additional financial metrics, InvestingPro subscribers have access to 8 more key tips about BeyondSpring’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.